这个规范将给全世界临床医师提供统一标准来比较和解释淋巴瘤治疗的临床试验，并将促进新治疗的进展。
The guidelines will provide clinicians worldwide with uniform criteria to compare and interpret clinical trials of lymphoma treatments and should facilitate the development of new therapies.
本文就近年来环境因素在非霍奇金淋巴瘤病因中作用的研究进展作一综述。
This paper reviewed the research advance on the role of environmental factors in the etiology of non-Hodgkin lymphoma.
二期的CheckMate - 140试验正在探索用nivolumab治疗经cd 20抗体和烷化剂治疗后进展的滤泡性淋巴瘤。
The phase II CheckMate-140 trial is exploring nivolumab (Opdivo) for patients with follicular lymphoma following progression on a CD20 antibody and an alkylating agent (NCT02038946).
应用推荐